Mavenclad Quickly Reduces MRI Lesions in Early MS, ORACLE-MS Data Show
Mavenclad (cladribine) reduces the number and volume of lesions in patients at risk of multiple sclerosis (MS) after a first clinical demyelinating event, a study based on Phase 3Ā trial data found. A demyelinating event occurs when myelin ā the protective coating around nerve fibers ā experiences damage; this…